Avaan Therapeutics

Avaan accelerates new drug development leveraging global resources, primarily, emerging markets like India and China. Avaan's business model is to license and develop drug candidates chosen by its founding team of former Pfizer senior researchers and executives. Primary focus areas are CNS, Oncology and Diabetes. The Avaan team in US/Europe/Asia comes with successful global registration experiences on Norvasc, Zoloft, Viagra, Diflucan, Zithromax, and several others. Management Team Dilip Mehta, MD, PhD, Chairman Rajnish Mishra, PhD, President & CEO Al Kraska, PhD, Medical Director Dave Dresback, PhD, SVP, Pharmaceutical Development Sunita Rajadhyaksha, MD, Head of India Operations Chirs Bonny, VP of Business Development Strategic Advisory Board Richard Fulmer, former VP Licensing and Development, Pfizer David McGibney, MD, former SVP Clinical Development, Pfizer Alex Giaquinto, PhD, former SVP Global Compliance, Schering Plough Larry Stambaugh, former Founder & CEO, Maxim Pharmaceuticals Robert Zerbe, MD, CEO of Quatrx Pharmaceuticals formerly SVP Clinical Research-Parke Davis, VP-Eli Lilly.